Dexrazoxane (ICRF-187) - the importance of sidechain hydroxyl group

By Weiss G.   Loyevsky M.   Gordeuk V.R.  

General Pharmacology, Vol. 32, Iss. 1, 1999-01 ,pp. : 155-158

Elsevier

Access to resources Recommend Favorite

Early detection of anthracycline-mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist 1

By Petrescu Lucian  

Canadian Journal of Physiology and Pharmacology, Vol. 91, Iss. 8, 2013-03 ,pp. : 601-607

NRC Research Press

Access to resources Recommend Favorite

Dexrazoxane: A Review of its Use as a Cardioprotective Agent in Patients Receiving Anthracycline-Based Chemotherapy

By Wiseman L.R.   Spencer C.M.  

Drugs, Vol. 56, Iss. 3, 1998-09 ,pp. : 385-403

Adis International

Access to resources Recommend Favorite

Anthracycline cardiotoxicity

By Jones Robin L   Swanton Charles   Ewer Michael S  

Expert Opinion on Drug Safety, Vol. 5, Iss. 6, 2006-11 ,pp. : 791-809

Informa Healthcare

Access to resources Recommend Favorite

Cardioprotective Effect of Dexrazoxane in Patients with Breast Cancer Treated with Anthracyclines in Adjuvant Setting: A 10-Year Single Institution Experience

By Testore Franco   Milanese Simona   Ceste Marco   Enrico de Conciliis   Parello Giuseppe   Lanfranco Claudio   Manfredi Roberto   Ferrero Gianfranco   Simoni Carlotta   Miglietta Loredana   Ferro Silvia   Giaretto Lorena   Bosso Giuseppina  

American Journal of Cardiovascular Drugs, Vol. 8, Iss. 4, 2008-01 ,pp. : 257-263

Adis International

Access to resources Recommend Favorite